查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933356

全球儿童疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

Pediatric Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 请询问到货日

价格

儿童疫苗市场成长因素

2025年全球儿童疫苗市场规模达到468.6亿美元，预计2026年将成长至504.6亿美元，到2034年将达到1214.6亿美元，预测期内年复合成长率（CAGR）为11.61%。北美地区将凭藉先进的医疗基础设施、强有力的政府支持和完善的免疫接种计划，在2025年占据市场主导地位，市场占有率为51.84%。儿童疫苗在预防儿童危及生命的疾病方面发挥着非常重要的作用，这些疾病包括疟疾、小儿麻痹、肺炎链球菌感染、麻疹和腮腺炎。各国政府和国际组织加大投资，包括盖兹基金会承诺在2025年向全球疫苗免疫联盟（Gavi）提供16亿美元的资金，加强全球免疫规划。

市场动态

市场驱动因素：市场主要受政府支持和大规模免疫规划的扩展所驱动。全球疫苗免疫联盟（Gavi）和联合国儿童基金会（UNICEF）等国际组织与各国政府合作进行疫苗采购和免疫接种计画。例如，2025年1月，联合国儿童基金会向17个疟疾流行非洲国家的儿童提供了超过980万剂疟疾疫苗，以支持常规免疫规划。这些努力提高疫苗的可及性、覆盖率和需求。

阻碍因素：疫苗犹豫仍然是主要的阻碍因素，尤其是在中低收入国家。对安全性的担忧、错误讯息以及对医疗卫生系统的不信任阻碍了疫苗的接种。世界卫生组织（WHO）于2019年将疫苗犹豫列为全球十大健康威胁之一，而新冠疫情进一步加剧了这种犹豫情绪。

机会：不断增加的研发投入带来了巨大的成长机会。目前，针对肠毒素性大肠桿菌（ETEC）和拉沙热等高传染性疾病的疫苗需求尚未被满足。例如，美国国立卫生研究院（NIH）在2024年报告指出，拉沙热每年在西非造成约 5000 人死亡，凸显了对新型疫苗的潜在需求。

挑战：缺乏冷藏基础设施是一项重大挑战。储存不当和冷链中断会导致疫苗浪费和效力降低。2021年，约有27亿人因缺乏冷链物流而无法可靠地获得疫苗，凸显了建立可靠的储存系统以支持免疫规划的必要性。

市场趋势

结合疫苗正成为一大趋势，简化了免疫接种程序，并有助于提高疫苗覆盖率。2025年7月，全球疫苗免疫联盟（Gavi）在茅利塔尼亚和塞内加尔推出了六价疫苗，可预防六种疾病：白喉、破伤风、百日咳、乙型肝炎、第二型流感嗜血桿菌（Hib）和小儿麻痹。结合疫苗有助于降低成本，并提高大规模疫苗接种活动的依从性。

细分市场分析

依类型划分：重组疫苗、结合疫苗和次单位疫苗领域因其广泛的适用性和高效性而占据领先地位。Merck公司与联合国儿童基金会合作建立伊波拉疫苗储备就是一个具有良好成长前景的例子。广泛用于对抗麻疹、腮腺炎和呼吸道合胞病毒（RSV）的减毒活疫苗也不断扩大，例如Codagenix公司于2023年进行的儿童CodaVax-RSV临床试验。灭活疫苗，例如印度的Covaxin和Corbevax，因其稳定性提高而备受关注。 mRNA疫苗，例如Moderna公司儿童的Spikevax，由于其可扩展性和监管批准的优势，预计将快速成长。

依疾病分类：病毒性疾病占市场主导地位，这主要受麻疹、腮腺炎、德国麻疹、人类乳突病毒（HPV）、流感和小儿麻痹等疾病高感染率的驱动。细菌疫苗，例如雅培公司用于预防肺炎球菌感染的PneumoShield 14疫苗，也呈现出显着的成长动能。

依给药途径：口服疫苗因其给药方便而占据市场主导地位，支持大规模免疫接种计划，例如巴布亚新几内亚的OPV3疫苗覆盖率，到2024年达到44%。注射疫苗由于能够提供全身免疫和长期保护，预计将稳定成长。

依通路：政府供应商透过与实施大规模免疫接种运动的组织合作，主导市场。例如，Panacea Biotech公司在2020年向联合国儿童基金会提供了4,000万剂口服小儿麻痹疫苗，价值520万美元。医院和零售药局由于疫苗的可及性和策略性合作伙伴关係（例如加拿大Wholehealth Pharmacy的Dose4Dose活动）而实现了成长。

区域展望

北美：2025年市场规模为209.4亿美元，预计2026年将达229亿美元。强大的基础设施、研发实力和合作是推动成长的主要动力。美国在该地区占据最大占有率，这主要得益于Pfizer公司婴儿呼吸道合胞病毒疫苗ABRYSVO等疫苗的批准。

欧洲：高疫苗接种覆盖率和政府计画是其占有较大占有率的重要因素。2023年核准的呼吸道合胞病毒疫苗ABRISVO等监管部门的核准，有助于缓解疫苗供应短缺问题。

亚太地区：由于麻疹等传染病的高发生率，该地区是成长最快的市场。全球疫苗免疫联盟（Gavi）预测，2025年东亚地区爆发大规模麻疹疫情，推动疫苗需求。

拉丁美洲、中东和非洲：由于疫苗接种计划和世卫组织计画（例如，目的是到2023年使非洲 500 多万儿童获得基本免疫恢復计划），该地区占据了很大占有率。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 主要国家和地区的监管环境
  • 主要国家和地区的疫苗接种覆盖率
  • 主要国家和地区的政府儿童免疫计划
  • 儿科疫苗市场的技术进步
  • 主要产业趋势：併购、商业合作等。

第5章 全球儿童疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 减毒活疫苗
    • 灭活疫苗
    • 重组/结合/次单位疫苗
    • mRNA疫苗
    • 病毒载体疫苗
    • 类毒素
    • 其他
  • 市场分析、洞察与预测：依疾病划分
    • 病毒性疾病
      • 甲型肝炎
      • 肝炎B
      • 小儿麻痹
      • 呼吸道合胞病毒（RSV）
      • 流感
      • 人类乳突病毒（HPV）
      • 麻疹、腮腺炎、德国麻疹（MMR）
      • 轮状病毒
      • 带状疱疹
      • 其他
    • 细菌性疾病
      • 肺炎链球菌感染
      • 百白破疫苗（DTP）
      • 脑膜炎双球菌感染
      • 其他
  • 市场分析、洞察与预测：依给药途径
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：依通路
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区
    • 北部美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美儿童疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲儿童疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第8章 亚太地区儿童疫苗市场分析市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲儿童疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲儿童疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家/地区
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市场占有率分析（2025年）
  • 公司简介
    • Merck &Co., Inc.
    • Sanofi.
    • Bharat Biotech.
    • GSK plc.
    • SINOVAC
    • Serum Institute of India Pvt. Ltd.
    • HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
    • Panacea Biotec
    • Bio Farma
    • AJ Vaccines A/S
    • Beijing Institute of Biological Products Co., Ltd.
Product Code: FBI113756

Growth Factors of pediatric vaccines Market

The global pediatric vaccines market was valued at USD 46.86 billion in 2025 and is projected to grow to USD 50.46 billion in 2026, reaching USD 121.46 billion by 2034, with a CAGR of 11.61% during the forecast period. North America dominated the market in 2025 with a share of 51.84%, driven by advanced healthcare infrastructure, strong government support, and robust vaccination programs. Pediatric vaccines play a critical role in preventing life-threatening diseases in children, including malaria, polio, pneumococcal infections, measles, mumps, and others. Increasing investments from governments and international organizations, such as the Gates Foundation's USD 1.6 billion support to Gavi in 2025, have bolstered vaccination programs worldwide.

Market Dynamics

Drivers: The market is primarily driven by government support and the expansion of mass vaccination programs. International organizations like Gavi and UNICEF are collaborating with governments for vaccine procurement and immunization initiatives. For example, in January 2025, UNICEF delivered over 9.8 million doses of malaria vaccines to children in 17 endemic African countries, supporting routine immunization programs. Such efforts increase vaccine accessibility, coverage, and demand.

Restraints: Vaccine hesitancy remains a major restraint, particularly in low- and middle-income countries. Safety concerns, myths, misinformation, and mistrust in healthcare systems have hampered adoption. WHO recognized vaccine hesitancy as a top ten global health threat in 2019, and the pandemic has further exacerbated reluctance.

Opportunities: Increasing research and development initiatives provide significant growth opportunities. There is an unmet need for vaccines against highly contagious diseases such as Enterotoxigenic Escherichia coli (ETEC) and Lassa fever. For instance, NIH reported in 2024 that Lassa fever causes approximately 5,000 deaths annually in West Africa, highlighting potential demand for novel vaccines.

Challenges: The lack of cold storage infrastructure poses significant challenges. Improper storage or breaks in the cold chain can lead to vaccine wastage and loss of potency. In 2021, around 2.7 billion people lacked dependable access to vaccines due to insufficient cold chain logistics, underscoring the need for reliable storage systems to support immunization programs.

Market Trends

Combination vaccines are emerging as a key trend, simplifying immunization schedules and increasing coverage. In July 2025, Gavi launched a hexavalent vaccine in Mauritania and Senegal, protecting against six diseases, including diphtheria, tetanus, pertussis, hepatitis B, Hib, and poliomyelitis. Combination vaccines reduce costs and improve compliance in mass vaccination campaigns.

Segmentation Analysis

By Type: The recombinant/conjugate/subunit vaccines segment dominates due to broad applications and high efficiency. Collaborations like Merck and UNICEF's Ebola vaccine stockpile highlight growth potential. Live attenuated vaccines, widely used against measles, mumps, and RSV, are also expanding, exemplified by Codagenix's CodaVax-RSV pediatric trial in 2023. Inactivated vaccines, such as India's Covaxin and Corbevax, are gaining traction due to enhanced stability. mRNA vaccines, including Moderna's Spikevax for children, are expected to grow rapidly due to scalability and regulatory approvals.

By Disease Indication: The viral diseases segment dominates, driven by high prevalence of measles, mumps, rubella, HPV, influenza, and polio. Bacterial vaccines, including Abbott's PneumoShield 14 for pneumococcal infections, are also witnessing significant growth.

By Route of Administration: Oral vaccines lead the market due to ease of administration, supporting mass immunization programs such as the OPV3 coverage of 44% in Papua New Guinea in 2024. Parenteral vaccines are expected to grow steadily, offering systemic immunity and long-term protection.

By Distribution Channel: Government suppliers dominate due to collaborations with operational entities for large-scale immunization campaigns. For example, Panacea Biotec supplied 40 million oral polio doses to UNICEF in 2020, valued at USD 5.2 million. Hospital and retail pharmacies are growing due to accessibility and strategic partnerships, such as Wholehealth Pharmacy's Dose4Dose campaign in Canada.

Regional Outlook

North America: Valued at USD 20.94 billion in 2025, projected to reach USD 22.9 billion in 2026, with strong infrastructure, R&D, and collaborations driving growth. The U.S. holds the largest regional share due to vaccine approvals like Pfizer's ABRYSVO for RSV in infants.

Europe: Substantial share driven by high immunization coverage and government programs. Regulatory approvals, such as Abrysvo for RSV in 2023, help close the vaccine supply gap.

Asia Pacific: Fastest-growing region due to high prevalence of infectious diseases like measles. Gavi reported significant measles outbreaks in East Asia in 2025, boosting vaccine demand.

Latin America & Middle East & Africa: Substantial share supported by vaccination initiatives and WHO programs, such as the Essential Immunization Recovery Plan vaccinating over 5 million children in Africa in 2023.

Competitive Landscape

The market is consolidated, with key players including Sanofi, Merck & Co., Inc., GSK plc., Bharat Biotech, Panacea Biotec, Serum Institute of India, SINOVAC, Haffkine Bio-Pharmaceutical, Bio Farma, AJ Vaccines, and Beijing Institute of Biological Products. Companies focus on new product launches, collaborations, and capacity expansion. For instance, Bharat Biotech collaborated with Bilthoven Biologicals in 2024 to strengthen oral polio vaccine production.

Conclusion

The global pediatric vaccines market is set to grow from USD 46.86 billion in 2025 to USD 50.46 billion in 2026, reaching USD 121.46 billion by 2034 at a CAGR of 11.61%. Growth is driven by government support, mass vaccination programs, R&D initiatives, combination vaccines, and strategic collaborations. North America dominates, while Asia Pacific emerges as the fastest-growing region. Despite challenges like cold chain limitations and vaccine hesitancy, expanding coverage and innovative products will propel the market forward.

Segmentation By Type

  • Live Attenuated
  • Inactivated
  • Recombinant/Conjugate/Subunit
  • mRNA Vaccine
  • Viral Vectors Vaccines
  • Toxoid
  • Others

By Disease Indication

  • Viral Diseases
    • Hepatitis
    • Hepatitis A
    • Hepatitis B
    • Polio
    • RSV
    • Influenza
    • HPV
    • Measles/Mumps/Rubella
    • Rotavirus
    • Shingles (Herpes Zoster)
    • Others
  • Bacterial Diseases
    • Pneumococcal Diseases
    • DTP
    • Meningococcal Diseases
    • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Children- By Key Countries/ Regions
  • 4.4. Technological Advancements in Pediatric Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Live Attenuated
    • 5.1.2. Inactivated
    • 5.1.3. Recombinant/Conjugate/Subunit
    • 5.1.4. mRNA Vaccine
    • 5.1.5. Viral Vectors Vaccines
    • 5.1.6. Toxoid
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Viral Diseases
      • 5.2.1.1. Hepatitis A
      • 5.2.1.2. Hepatitis B
      • 5.2.1.3. Polio
      • 5.2.1.4. RSV
      • 5.2.1.5. Influenza
      • 5.2.1.6. HPV
      • 5.2.1.7. MMR
      • 5.2.1.8. Rotavirus
      • 5.2.1.9. Shingles
      • 5.2.1.10. Others
    • 5.2.2. Bacterial Diseases
      • 5.2.2.1. Pneumococcal Diseases
      • 5.2.2.2. DTP
      • 5.2.2.3. Meningococcal Diseases
      • 5.2.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Live Attenuated
    • 6.1.2. Inactivated
    • 6.1.3. Recombinant/Conjugate/Subunit
    • 6.1.4. mRNA Vaccine
    • 6.1.5. Viral Vectors Vaccines
    • 6.1.6. Toxoid
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Viral Diseases
      • 6.2.1.1. Hepatitis A
      • 6.2.1.2. Hepatitis B
      • 6.2.1.3. Polio
      • 6.2.1.4. RSV
      • 6.2.1.5. Influenza
      • 6.2.1.6. HPV
      • 6.2.1.7. MMR
      • 6.2.1.8. Rotavirus
      • 6.2.1.9. Shingles
      • 6.2.1.10. Others
    • 6.2.2. Bacterial Diseases
      • 6.2.2.1. Pneumococcal Diseases
      • 6.2.2.2. DTP
      • 6.2.2.3. Meningococcal Diseases
      • 6.2.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Live Attenuated
    • 7.1.2. Inactivated
    • 7.1.3. Recombinant/Conjugate/Subunit
    • 7.1.4. mRNA Vaccine
    • 7.1.5. Viral Vectors Vaccines
    • 7.1.6. Toxoid
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Viral Diseases
      • 7.2.1.1. Hepatitis A
      • 7.2.1.2. Hepatitis B
      • 7.2.1.3. Polio
      • 7.2.1.4. RSV
      • 7.2.1.5. Influenza
      • 7.2.1.6. HPV
      • 7.2.1.7. MMR
      • 7.2.1.8. Rotavirus
      • 7.2.1.9. Shingles
      • 7.2.1.10. Others
    • 7.2.2. Bacterial Diseases
      • 7.2.2.1. Pneumococcal Diseases
      • 7.2.2.2. DTP
      • 7.2.2.3. Meningococcal Diseases
      • 7.2.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Live Attenuated
    • 8.1.2. Inactivated
    • 8.1.3. Recombinant/Conjugate/Subunit
    • 8.1.4. mRNA Vaccine
    • 8.1.5. Viral Vectors Vaccines
    • 8.1.6. Toxoid
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Viral Diseases
      • 8.2.1.1. Hepatitis A
      • 8.2.1.2. Hepatitis B
      • 8.2.1.3. Polio
      • 8.2.1.4. RSV
      • 8.2.1.5. Influenza
      • 8.2.1.6. HPV
      • 8.2.1.7. MMR
      • 8.2.1.8. Rotavirus
      • 8.2.1.9. Shingles
      • 8.2.1.10. Others
    • 8.2.2. Bacterial Diseases
      • 8.2.2.1. Pneumococcal Diseases
      • 8.2.2.2. DTP
      • 8.2.2.3. Meningococcal Diseases
      • 8.2.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Live Attenuated
    • 9.1.2. Inactivated
    • 9.1.3. Recombinant/Conjugate/Subunit
    • 9.1.4. mRNA Vaccine
    • 9.1.5. Viral Vectors Vaccines
    • 9.1.6. Toxoid
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Viral Diseases
      • 9.2.1.1. Hepatitis A
      • 9.2.1.2. Hepatitis B
      • 9.2.1.3. Polio
      • 9.2.1.4. RSV
      • 9.2.1.5. Influenza
      • 9.2.1.6. HPV
      • 9.2.1.7. MMR
      • 9.2.1.8. Rotavirus
      • 9.2.1.9. Shingles
      • 9.2.1.10. Others
    • 9.2.2. Bacterial Diseases
      • 9.2.2.1. Pneumococcal Diseases
      • 9.2.2.2. DTP
      • 9.2.2.3. Meningococcal Diseases
      • 9.2.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Live Attenuated
    • 10.1.2. Inactivated
    • 10.1.3. Recombinant/Conjugate/Subunit
    • 10.1.4. mRNA Vaccine
    • 10.1.5. Viral Vectors Vaccines
    • 10.1.6. Toxoid
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Viral Diseases
      • 10.2.1.1. Hepatitis A
      • 10.2.1.2. Hepatitis B
      • 10.2.1.3. Polio
      • 10.2.1.4. RSV
      • 10.2.1.5. Influenza
      • 10.2.1.6. HPV
      • 10.2.1.7. MMR
      • 10.2.1.8. Rotavirus
      • 10.2.1.9. Shingles
      • 10.2.1.10. Others
    • 10.2.2. Bacterial Diseases
      • 10.2.2.1. Pneumococcal Diseases
      • 10.2.2.2. DTP
      • 10.2.2.3. Meningococcal Diseases
      • 10.2.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co., Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bharat Biotech.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. GSK plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. SINOVAC
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Serum Institute of India Pvt. Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Panacea Biotec
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bio Farma
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. AJ Vaccines A/S
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Beijing Institute of Biological Products Co., Ltd.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 2: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 3: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 4: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 5: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 6: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 7: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 8: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 9: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 10: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 11: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 12: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 13: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 14: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 15: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 16: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 17: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 18: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 19: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 20: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 21: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 23: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 24: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 25: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 26: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 27: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 28: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 30: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 31: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 32: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 33: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 34: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 35: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 37: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 38: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 39: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 40: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 41: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 42: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Pediatric Vaccines Market Revenue Breakdown (USD billion, %), By Region, 2025 & 2034
  • Figure 2: Global Pediatric Vaccines Market Value Share (%), By Type, 2025 & 2034
  • Figure 3: Global Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025 & 2034
  • Figure 4: Global Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 5: Global Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 6: Global Pediatric Vaccines Market Value Share (%), By Region, 2025 & 2034
  • Figure 7: North America Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 8: North America Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 9: North America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 10: North America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 11: North America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 12: North America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 13: North America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 14: North America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 15: North America Pediatric Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Pediatric Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 18: Europe Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 19: Europe Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 20: Europe Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 21: Europe Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 22: Europe Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 23: Europe Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 24: Europe Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 25: Europe Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 28: Asia Pacific Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 29: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 30: Asia Pacific Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 31: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 33: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 35: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 38: Latin America Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 39: Latin America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 40: Latin America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 41: Latin America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 42: Latin America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 43: Latin America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 45: Latin America Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 48: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 49: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 50: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 51: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 53: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 55: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Pediatric Vaccines Market Share (%), By Company, 2025